As the global trade in goods flattens, the flow of services in Asia is surging; the service sector now employs more than ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional ...

MIRA Pharmaceuticals (MIRA) has signed a binding letter of intent to acquire SKNY Pharmaceuticals. The transaction includes a $5M capital ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Announced in December 2024, David Enloe joins as the division’s CEO. He has experience leading life science CDMOs such as ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

PhaseV, a leader in AI/ML-driven clinical development, announced today that it will demonstrate new capabilities of its ...

BioAFM instruments are designed to measure soft, fragile, and complex samples, including single molecules, nucleic acids, ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.